Advancing medicine,
improving lives.
                      - 
                          Brisbane
                          
Australia’s only Phase l unit dedicated to early clinical development of New Biological Entities (NBE’s), Biosimilars and Vaccines.
- 
                                          
                                          
60-bed facility, co-located within the Royal Brisbane and Women’s Hospital
 - 
                                          
                                          
275 trials completed
 
 - 
                                          
                                          
 - 
                          Melbourne
                          
A leading Phase I facility capable of delivering patients for pharmacokinetic studies in hepatic and renal patients.
- 
                                          
                                          
Over 111 beds (95 inpatient, 16 outpatient), co-located within the Alfred Hospital
 - 
                                          
                                          
450 trials completed
 
 - 
                                          
                                          
 - 
                          Minneapolis
                          
A leading Phase I facility capable of delivering patients for pharmacokinetic studies in hepatic and renal patients.
- 
                                          
                                          
50-bed facility, co-located within the University Enterprise Labs (UEL) and Medical Alley
 - 
                                          
                                          
120 trials completed
 
 - 
                                          
                                          
 - 
                          London
                          
A world-renowned early phase unit specialising in first-in-human trials and studies in healthy and patient volunteers.
- 
                                          
                                          
145-bed facility, purpose-built for Phase I research and based in Central London
 - 
                                          
                                          
Over 1,000 trials completed for global biopharma and biotech sponsors
 
 -